These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro. Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118 [TBL] [Abstract][Full Text] [Related]
25. Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma. Mogi A; Koga K; Aoki M; Hamasaki M; Uesugi N; Iwasaki A; Shirakusa T; Tamura K; Nabeshima K Virchows Arch; 2013 Jan; 462(1):83-93. PubMed ID: 23187830 [TBL] [Abstract][Full Text] [Related]
30. Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition. Quispel-Janssen JM; Badhai J; Schunselaar L; Price S; Brammeld J; Iorio F; Kolluri K; Garnett M; Berns A; Baas P; McDermott U; Neefjes J; Alifrangis C Clin Cancer Res; 2018 Jan; 24(1):84-94. PubMed ID: 29061644 [No Abstract] [Full Text] [Related]
31. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study. Arimura K; Hiroshima K; Nagashima Y; Nakazawa T; Ogihara A; Orimo M; Sato Y; Katsura H; Kanzaki M; Kondo M; Tagaya E BMC Cancer; 2023 Dec; 23(1):1206. PubMed ID: 38062416 [TBL] [Abstract][Full Text] [Related]
32. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma. Nguyen BH; Montgomery R; Fadia M; Wang J; Ali S Asia Pac J Clin Oncol; 2018 Feb; 14(1):69-73. PubMed ID: 29105302 [TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical Expression of Aquaporin-1 in Fluoro-Edenite-Induced Malignant Mesothelioma: A Preliminary Report. Angelico G; Caltabiano R; Loreto C; Ieni A; Tuccari G; Ledda C; Rapisarda V Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495596 [TBL] [Abstract][Full Text] [Related]
34. Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). Cedrés S; Ponce-Aix S; Pardo-Aranda N; Navarro-Mendivil A; Martinez-Marti A; Zugazagoitia J; Sansano I; Montoro MA; Enguita A; Felip E Lung Cancer; 2016 Jun; 96():1-6. PubMed ID: 27133741 [TBL] [Abstract][Full Text] [Related]
35. Up-regulation of DDX39 in human malignant pleural mesothelioma cell lines compared to normal pleural mesothelial cells. Kuramitsu Y; Tominaga W; Baron B; Tokuda K; Wang Y; Kitagawa T; Nakamura K Anticancer Res; 2013 Jun; 33(6):2557-60. PubMed ID: 23749908 [TBL] [Abstract][Full Text] [Related]
36. Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma. Mundt F; Johansson HJ; Forshed J; Arslan S; Metintas M; Dobra K; Lehtiö J; Hjerpe A Mol Cell Proteomics; 2014 Mar; 13(3):701-15. PubMed ID: 24361865 [TBL] [Abstract][Full Text] [Related]
37. Prognostic role of secreted protein acidic and rich in cysteine in patients with solid tumors. Ma Y; Chen H; Ma H; Yao Z; Hu J; Ma J; Zhang X; Chen G; Liu Y Saudi Med J; 2019 Aug; 40(8):755-765. PubMed ID: 31423511 [TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis. Tian L; Zeng R; Wang X; Shen C; Lai Y; Wang M; Che G Oncotarget; 2017 Jul; 8(28):46425-46435. PubMed ID: 28507279 [TBL] [Abstract][Full Text] [Related]
39. Impact of Secreted Protein Acidic and Rich in Cysteine (SPARC) Expression on Prognosis After Surgical Resection for Biliary Carcinoma. Toyota K; Murakami Y; Kondo N; Uemura K; Nakagawa N; Takahashi S; Sueda T J Gastrointest Surg; 2017 Jun; 21(6):990-999. PubMed ID: 28342122 [TBL] [Abstract][Full Text] [Related]